Stuttgart - Delayed Quote EUR

BeiGene Ltd (49BA.SG)

214.00

+4.00

+(1.90%)

At close: May 29 at 8:14:45 AM GMT+2

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

SAN CARLOS, Calif. & BASEL, Switzerland, May 27, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company formerly known as BeiGene, Ltd., today announced its new name and redomiciliation to Switzerland are officially in effect, marking a significant milestone in the Company’s evolution.

Business Wire 2 days ago

BEIGF

ONC
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

SAN CARLOS, Calif., May 27, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with recurrent, not amenable to curative surgery or

Business Wire 2 days ago

BEIGF

ONC
Exploring US High Growth Tech Stocks In May 2025

Over the last 7 days, the United States market has dropped 1.1%, yet it remains up by 9.1% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks that can capitalize on these positive earnings projections is crucial for investors seeking opportunities in a dynamic and evolving sector.

Simply Wall St. 7 days ago

CYBR

SPRY

BEIGF
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

SAN CARLOS, Calif., May 22, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share 23 abstracts featuring new data across its hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, May 30 – June 3, 2025. With two abstracts selected for rapid oral presentation, these data reflect the Company’s vision to address cancer acr

Business Wire 7 days ago

BEIGF

ONC
BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies

BeiGene (NasdaqGS:ONC) recently announced comprehensive analyses from clinical trials at EHA2025, focusing on hematological malignancies, reflecting its commitment to advancing treatment options. However, the company’s share price declined by 2.46% over the last quarter. Despite the unveiling of promising clinical data and revenue growth, these developments seem to have countered broader market trends, where major indices like the S&P 500 and Nasdaq Composite showed gains. BeiGene's improved...

Simply Wall St. 14 days ago

BEIGF

ONC
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

SAN CARLOS, Calif., May 14, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUK

Business Wire 15 days ago

BEIGF

ONC
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

SAN CARLOS, Calif., May 13, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat at 10 a.m. EDT.

Business Wire 16 days ago

BEIGF

ONC
BeiGene First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

BeiGene ( NASDAQ:ONC ) First Quarter 2025 Results Key Financial Results Revenue: US$1.12b (up 49% from 1Q 2024). Net...

Simply Wall St. 18 days ago

BEIGF

ONC
Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Last week, you might have seen that BeiGene, Ltd. ( NASDAQ:ONC ) released its first-quarter result to the market. The...

Simply Wall St. 19 days ago

BEIGF

ONC
BeiGene Announces First Quarter 2025 Financial Results and Business Updates

SAN CARLOS, Calif., May 07, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

Business Wire 22 days ago

BEIGF

ONC
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

SAN CARLOS, Calif., April 29, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding.

Business Wire 30 days ago

BEIGF

ONC
3 Stocks That Could Be Trading Below Their Estimated Fair Value

Over the last 7 days, the United States market has risen by 7.1%, contributing to a 7.7% increase over the past year, with earnings growth anticipated at 14% per annum in the coming years. In this environment, identifying stocks that may be trading below their estimated fair value can offer potential opportunities for investors looking to capitalize on future growth prospects.

Simply Wall St. 30 days ago

BEIGF

ONC

WIX
Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?

BeiGene stock has formed an early-stage base with a buy point of 287.88 ahead of its first-quarter results on May 7.

Investor's Business Daily last month

BEIGF

ONC
Exploring 3 High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has experienced a 1.7% drop, but it has shown resilience with a 3.6% rise over the past year and an anticipated annual earnings growth of 13%. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability in alignment with these positive long-term market trends.

Simply Wall St. last month

NBIX

BEIGF

ONC
BeiGene to Announce First Quarter 2025 Financial Results on May 7

SAN CARLOS, Calif., April 17, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.

Business Wire last month

BEIGF

ONC
BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA

BeiGene (NasdaqGS:ONC) has climbed 32% over the past quarter, against a backdrop of significant industry challenges and broad market declines. The company's positive momentum can be attributed to the European Medicines Agency's positive opinion on TEVIMBRA, recommended for small cell lung cancer treatment, and its recent addition to the Hang Seng China Enterprises Index. These developments underscore BeiGene's expanding presence and potential in the competitive oncology market, providing a...

Simply Wall St. last month

BEIGF

ONC
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

SAN CARLOS, Calif., April 03, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.

Business Wire last month

BEIGF

ONC
Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value

Amid recent market volatility, driven by concerns over new tariffs and economic data, investors are keenly observing stocks that may be undervalued in the current climate. Identifying stocks priced below their estimated fair value can offer potential opportunities for those looking to navigate these uncertain times effectively.

Simply Wall St. last month

NFG

DRVN

BEIGF
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

SAN CARLOS, Calif., March 31, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lun

Business Wire last month

BEIGF

ONC
FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction

BeiGene (NasdaqGS:ONC) experienced a significant 29% price increase over the last quarter, supported by the FDA approval of TEVIMBRA for treating esophageal squamous cell carcinoma, a key development signalling the company's progress in oncology. This approval was based on favorable results from the RATIONALE-306 trial, demonstrating improved overall survival for patients. Further bolstering investor confidence were BeiGene's improved financial reports, showcasing a rise in revenue to $3.8...

Simply Wall St. 2 months ago

BEIGF

ONC

Performance Overview

Return	49BA.SG	HANG SENG INDEX (^HSI)
YTD	+22.99%	+15.82%
1-Year	+55.07%	+27.45%
3-Year	+79.83%	+9.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BeiGene Ltd (49BA.SG)

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

Exploring US High Growth Tech Stocks In May 2025

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

BeiGene First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

3 Stocks That Could Be Trading Below Their Estimated Fair Value

Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?

Exploring 3 High Growth Tech Stocks In The US Market

BeiGene to Announce First Quarter 2025 Financial Results on May 7

BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction

Performance Overview